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Abstracts / Urological Science 27 (2016) S53eS83S60extremities, and rarely arise from visceral organ. Herein, we report a rare
case of malignant glomus tumor arising from kidney.
Case report: A 46 years oldmanwith history of nasopharynx cancer, status
post chemoraiation therapy, has right renal tumor found incidentally on a
pulmonary computed tomography scan for following of nasopharynx
cancer. A contrast enhanced computed tomography of abdomen showed a
tumor about 4.4cm with heterogenous enhancement over medial upper
pole of right kidney. The patient undertook laparoscopic right radical ne-
phrectomy with right adrenalectomy and recovered well after the opera-
tion. According to the histologic and immunohistochemical examination,
the tumor is diagnosed as malignant glomus tumor.
Conclusion: Glomus tumors resemble glomus body, which is associated
with body temperature regulation. Glomus tumors usually occur in the
extremities, most common the subungual region of the ﬁngers. Visceral
organs are uncommon site involving development of glomus tumors.
Glomus tumors arising from kidney are extremely rare, with a few cases
described before.
It is difﬁcult to differentiate glomus tumor from other renal malignany
preoperatively through imaging study. Histolgoy and immunohistochem-
ical study are necessary tomake a diagnosis of glomus tumor of the kidney.
Renal glomus tumors are usually benign with good outcome and prog-
nosis, with one exception of malignant glomus tumor been reported. We
report a case of malignant glomus tumor of kidney. To our knowledge, this
is the second case of malignant renal glomus tumor reported. Given the
small number of cases reported to date and relative short-term follow up,
close clinical follow-up is necessary.
NDP027:
CANCER-TO-CANCER METASTASIS: BREAST CANCER METASTASIZED
INTO RENAL CELL CARCINOMA e A CASE REPORT
Wei-Min Tsai. Divisions of Urology, Department of Surgery, Mennonite
Christian Hospital, Hualien, Taiwan
A 42-year-old female patient, a case of left breast mass with skin ulceration
diagnosed by biopsy, was accidentally found to have right renal mass on CT
(computerized tomography) during cancer staging workup. Metastases to
axillary lymph nodes, bone and liver were also noted at the same time.
Second opinion was sought from Urologist for the right renal mass while
she underwent CCRT (combined chemo-radiotherapy). Biopsy of right
renal mass revealed renal cell carcinoma (RCC) and radical nephrectomy
was done 2 months after initial CCRT. Staging for the RCC was T1aN0M0
while breast cancer stage was T4N1M1.
There are 7 cases (including the current case) reported to have breast
cancer metastasized into RCC. Their ages range from 42e75. Four of them
have RCC on the same side as their breast cancers. Two of the cases are
found only after autopsy. Time lapse in diagnosis of RCC after breast cancer
is from one month to 30 years.
Less than 50 documented cases of cancer-to-cancer metastasis have been
reported. RCC is the most common tumor found to coexist with other
malignancies and is the recipient tumor in cancer-to-cancer metastasis in
65e75% of the reported cases. Because of the “terminal stages” when
kidneys are involved in breast cancer patients, RCC may be under-
diagnosed in these patients and cancer-to-cancer metastasis might be
much more frequent.
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UNUSUAL PRESENTATION OF DIRECT INTRA-PERITONEAL METASTASES
COMPLICATED WITH MASSIVE ASCITES FROM POOR DIFFERENTIATION
BLADDER TUMOR: A CASE REPORT
Yu-Hua Shau 1,2, Sheng-Tang Wu1, Shou-Hung Tang 1, Tai-Lung Cha 1,
Chih-Wei Tsao 1, En Meng 1, Dah-Shyong Yu 1, Guang-Huan Sun 1,
Chien-Chang Kao 1. 1Division of Urology, Department of Surgery,
Tri-Service General Hospital, National Defense Medical Center, Taipei,
Taiwan, ROC; 2Division of Urology, Department of surgery, Taoyuan armed
forces general hospital, Taiwan
Purpose: Plasmacytoid urothelial carcinoma variant is a rare histological
ﬁnding, which was ﬁrst described in 1991. Since then, only 70 cases have
been described in the literature and the biological behavior of this variantof urothelial carcinoma is still not well known. The plasmacytoid variant is
usually very aggressive; distant metastases are detected in up to 60 % of
cases at the time of diagnosis with special predilection for dissemination
through the fascia causing peritoneal carcinomatosis. Despite being a tu-
mor of poor prognosis, it has been shown to be chemosensitive. This report
describes a patient who have adenocarcinoma of colon and plasmacytoid
urothelial carcinoma variant of bladder. Clinically mimicking a massive
ascites and pitting edema of bilateral low legs without hematuria.
Case report: The 74-year-old male suffered from abdominal fullness and
bilateral low legs edema in mid-Aug, 2015. He had visited our GU outpa-
tient department and abdominal sonography was performed which
revealed massive ascites. He was referred to our ER on 2015/08 and
abdomen CT revealed three important ﬁnding (1) massive ascites and
omental cake, (2) Enlarged nodes in the para-aortic space, (3) Diffuse
irregular wall thickening in the urinary bladder, which suspected bladder.
In ER, abdominal paracentesis was done and cytology was collected. After
admission, tumor markers were checked and CEA elevated, so he was
scheduled to receiving colonoscopy and one 3cm colon tumorwas found at
sigmoid colon and several small nodules over whole colon. He also
received cystoscopy and non-papillary type bladder tumor was found.
After colon tumor biopsy and transurethral resection of bladder tumor, we
conﬁrmed that the patient have double cancer. Ascites cytology suggested
malignancy and peritoneal carcinomatosis cannot be rule out. We had used
ascites immunohistochemistry method for search primary tumor. Usually,
we think the origin is form the colon tumor. However, this is not what we
think as a patient. The histological diagnosis of the tumor was plasmacy-
toid urothelial carcinoma variant of bladder with peritoneal metastasis. He
was referred to oncology for further chemotherapy.
Conclusion: The plasmacytoid variant of urothelial carcinoma, deﬁned as
the presence of plasma cells similar to myeloma, has had an increase in
prevalence in recent years, which has aided in increasing our under-
standing of its biological behavior and clinical implications. It is considered
to be a type of carcinoma with an aggressive histological behavior with
special predilection for local invasion of fascia and adjacent tissue. It also
has a poor prognosis with a signiﬁcant percentage of patients having
metastases at diagnosis, especially intraperitoneal dissemination.
NDP029:
SALVAGE HIFU (HIGH-INTENSITY FOCUSED ULTRASOUND) IN THE
MANAGEMENT OF PROSTATE RESIDUAL TUMOR AFTER PRIMARY HIFU
Sharjil Wahid, Guan-Lin Huang, Po Hui Chiang. Department of Urology,
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Purpose: Recent data on the Ablatherm® HIFU device shows a 5-year
biochemical disease-free survival rate of 80e85%. 15e20% patients have
residual tumor when treated by HIFU for localized prostate cancer. HIFU
can also be used as salvage therapy after radical prostatectomy and
external-beam radiotherapy. There has been little or no literature about
this novel use of secondary HIFU. We present our data of using secondary
HIFU in the management of residual tumor after primary HIFU, with the
aim of determining efﬁcacy and safety of this modality.
Materials and Methods: A total of 168 patients underwent HIFU for pri-
mary treatment of localized prostate cancer from December 2009 to July
2015. 12 patients were offered HIFU as secondary salvage management. All
of these had histologically proven residual/ recurrent prostate cancer after
primary HIFU. 8 were given HIFU as the only management, 3 were given
hormone therapy with HIFU, and 1 received HIFU, hormone therapy and
radiotherapy.
Results: The mean pre-secondary HIFU PSA was 2.28 ng/ml (0.52e4.77).
After salvage HIFU, 8 out of 12 patients (66.7%) achieved nadir PSA less
than 50% of pre-treatment values. These showed biochemical disease free
survival. Mean post-treatment nadir PSA value was 0.39 ng/ml
(0.02e0.75). Time to achieve post-treatment PSA nadir was 1.13 months
(1e2). The 8 patients had mean post-treatment PSA of 0.78 ng/ml
(0.02e1.78) when followed up over a mean period of 11.25 months (1e20),
demonstrating biochemical disease free survival.
3 patients (25%) had elevation of PSA, mean 5.6 ng/ml (3.17e7.52), after
salvage HIFU. These were registered as failures. One patient was excluded
from the study because of negative prostate biopsy, which meant that it
could not be ascertained that the disease was localized or metastatic.
